Home›Semaglutide

Semaglutide

Also known as: Ozempic

GLP-1 Receptor AgonistGlucagon-like Peptide-1 (GLP-1) Agonists

Route: Subcutaneous

5 interactions on record⛔ Black Box Warning

Semaglutide has 5 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Insulin Human, Sulfonylurea, Levothyroxine. Patients taking Semaglutide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 5
Major: 2
Moderate: 3

Major (2)

Semaglutide + Insulin Human— Semaglutide lowers blood glucose and increases risk of hypoglycemia when used with insulin. Dose reduction of insulin sh…
Semaglutide + Sulfonylurea— Increased risk of hypoglycemia, including severe hypoglycemia. Consider reducing sulfonylurea dose when initiating semag…

Moderate (3)

Semaglutide + Levothyroxine— Semaglutide tablet increased levothyroxine exposure by 33%. Monitor effects and consider increased clinical monitoring w…
Semaglutide + Oral Medications— WEGOVY delays gastric emptying and may impact absorption of concomitantly administered oral medications. Monitor effects…
Semaglutide + Oral Medications (General)— Semaglutide delays gastric emptying and may impact absorption of concomitantly administered oral medications. Use with c…

Semaglutide + Insulin Human⚠️Major

Semaglutide lowers blood glucose and increases risk of hypoglycemia when used with insulin. Dose reduction of insulin should be considered when initiating semaglutide.

Semaglutide + Sulfonylurea⚠️Major

Increased risk of hypoglycemia, including severe hypoglycemia. Consider reducing sulfonylurea dose when initiating semaglutide.

Semaglutide + Levothyroxine🟡Moderate

Semaglutide tablet increased levothyroxine exposure by 33%. Monitor effects and consider increased clinical monitoring with concomitant use.

Semaglutide + Oral Medications🟡Moderate

WEGOVY delays gastric emptying and may impact absorption of concomitantly administered oral medications. Monitor effects of oral medications.

Semaglutide + Oral Medications (General)🟡Moderate

Semaglutide delays gastric emptying and may impact absorption of concomitantly administered oral medications. Use with caution.

⛔ FDA Black Box Warning

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )] . • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of OZEMPIC and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] . WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined ( 5.1 , 13.1 ). • OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors ( 4 , 5.1 ).

Contraindications

4 CONTRAINDICATIONS OZEMPIC is contraindicated in patients with: • A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )] . • A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.7 )] . • Personal or family history of MTC or in patients with MEN 2 ( 4 ). • Serious hypersensitivity reaction to semaglutide or any of the excipients in OZEMPIC ( 4 ).

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy (see Clinical Considerations) . Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. OZEMPIC should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In pregnant rats administered semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at maternal clinical exposure based on AUC. In rabbits and cynomolgus monkeys administered semaglutide during organogenesis, early pregnancy losses or structural abnormalities were observed at clinical exposure (rabbit) and ≥2-fold the MRHD (monkey). These findings coincided with a marked maternal body weight loss in both animal species (see Data) . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes with a peri-conceptional HbA 1c >7 and has been reported to be as high as 20 to 25% in women with a peri-conceptional HbA 1c >10. The estimated background risk of miscarriage for the indicated population is unknown. Clinical Considerations Disease-Associated Maternal and/or Embryo/fetal Risk Hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes. Poorly controlled diabetes during pregnancy increases the maternal risk for diabetic ketoacidosis, pre- eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomi

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.